ERBB2 and head and neck squamous cell carcinoma: Ye et al. found STING could sensitize head and neck squamous cell carcinoma cells to apatinib by decreasing ERBB2 expression and combination of STING agonist with apatinib synergistically ameliorated acquired apatinib resistance [17].